2GVG
Crystal Structure of human NMPRTase and its complex with NMN
Summary for 2GVG
| Entry DOI | 10.2210/pdb2gvg/pdb |
| Related | 2GVJ |
| Descriptor | Nicotinamide phosphoribosyltransferase, PHOSPHATE ION, BETA-NICOTINAMIDE RIBOSE MONOPHOSPHATE, ... (4 entities in total) |
| Functional Keywords | nmprtase, visfatin, pbef, crystal, cancer, transferase |
| Biological source | Homo sapiens (human) |
| Cellular location | Cytoplasm (By similarity): P43490 |
| Total number of polymer chains | 6 |
| Total formula weight | 336720.64 |
| Authors | Khan, J.A.,Tao, X.,Tong, L. (deposition date: 2006-05-02, release date: 2006-06-20, Last modification date: 2024-02-14) |
| Primary citation | Khan, J.A.,Tao, X.,Tong, L. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat.Struct.Mol.Biol., 13:582-588, 2006 Cited by PubMed Abstract: Nicotinamide phosphoribosyltransferase (NMPRTase) has a crucial role in the salvage pathway of NAD+ biosynthesis, and a potent inhibitor of NMPRTase, FK866, can reduce cellular NAD+ levels and induce apoptosis in tumors. We have determined the crystal structures at up to 2.1-A resolution of human and murine NMPRTase, alone and in complex with the reaction product nicotinamide mononucleotide or the inhibitor FK866. The structures suggest that Asp219 is a determinant of substrate specificity of NMPRTase, which is confirmed by our mutagenesis studies. FK866 is bound in a tunnel at the interface of the NMPRTase dimer, and mutations in this binding site can abolish the inhibition by FK866. Contrary to current knowledge, the structures show that FK866 should compete directly with the nicotinamide substrate. Our structural and biochemical studies provide a starting point for the development of new anticancer agents. PubMed: 16783377DOI: 10.1038/nsmb1105 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.2 Å) |
Structure validation
Download full validation report
